NCT02576314

Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients

Efficacy and Safety Study of Sofosbuvir Containing Regimens in Subjects With Chronic Hepatitis C Virus Genotype 3 Infection

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Humanity and Health Research Centre · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety, tolerability, and efficacy of Sofosbuvir containing regimens in treatment-naive or treatment-experienced patients with HCV genotype 3 infection.

Conditions

• Chronic Hepatitis C Infection

Interventions

Type	Name	Description
DRUG	sofosbuvir and daclatasvir	Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60 mg tablet administered orally once daily.
DRUG	ledipasvir/sofosbuvir	Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally. once daily;

Timeline

• Start date: 2015-05-01
• Primary completion: 2017-12-31
• Completion: 2018-03-15
• First posted: 2015-10-15
• Last updated: 2018-03-19

Locations

2 sites across 1 country: China